Xspray Pharma AB (publ) (LON:0GHZ)

Market Cap	55.70M -39.4%
Revenue (ttm)	196.23K
Net Income	-13.09M
EPS	-0.33
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,200
Open	16.10
Previous Close	n/a
Day's Range	16.10 - 16.10
52-Week Range	14.24 - 61.40
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 24
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GHZ

Financial Performance

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error